Top-Rated Stocks NASDAQ:RXDX Prometheus Biosciences - RXDX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Prometheus Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $109.67 -3.99 (-3.51%) (As of 02/1/2023 12:00 AM ET) Add Compare Share Share Today's Range$106.32▼$114.5150-Day Range$36.06▼$121.2552-Week Range$21.50▼$122.75Volume475,838 shsAverage Volume503,909 shsMarket Capitalization$4.60 billionP/E RatioN/ADividend YieldN/APrice Target$117.10 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Prometheus Biosciences MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside6.8% Upside$117.10 Price TargetShort InterestBearish10.91% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.16Based on 4 Articles This WeekInsider TradingSelling Shares$3.57 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.43) to ($3.59) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.21 out of 5 starsMedical Sector1028th out of 1,053 stocksPharmaceutical Preparations Industry504th out of 519 stocks 1.5 Analyst's Opinion Consensus RatingPrometheus Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $117.10, Prometheus Biosciences has a forecasted upside of 6.8% from its current price of $109.67.Amount of Analyst CoveragePrometheus Biosciences has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.91% of the float of Prometheus Biosciences has been sold short.Short Interest Ratio / Days to CoverPrometheus Biosciences has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Prometheus Biosciences has recently increased by 2.66%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldPrometheus Biosciences does not currently pay a dividend.Dividend GrowthPrometheus Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RXDX. Previous Next 2.9 News and Social Media Coverage News SentimentPrometheus Biosciences has a news sentiment score of 1.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Prometheus Biosciences this week, compared to 1 article on an average week.Search InterestOnly 9 people have searched for RXDX on MarketBeat in the last 30 days. This is a decrease of -31% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Prometheus Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -82% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Prometheus Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,569,750.00 in company stock.Percentage Held by InsidersOnly 3.40% of the stock of Prometheus Biosciences is held by insiders.Percentage Held by Institutions78.31% of the stock of Prometheus Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Prometheus Biosciences are expected to decrease in the coming year, from ($3.43) to ($3.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Prometheus Biosciences is -32.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Prometheus Biosciences is -32.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPrometheus Biosciences has a P/B Ratio of 18.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Prometheus Biosciences (NASDAQ:RXDX) StockPrometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR600, an anti-tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; PR1800, an anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California.Read More Receive RXDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Prometheus Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address RXDX Stock News HeadlinesJanuary 31, 2023 | markets.businessinsider.comAnalyst Expectations for Prometheus Biosciences's FutureJanuary 20, 2023 | 247wallst.com5 Best and Worst Performing Mid-Cap Stocks in Q4 2022February 2, 2023 | Tradewins (Ad)Know Your Profit Potential BEFORE You Trade!I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! January 10, 2023 | finance.yahoo.comWall Street Analysts Believe Prometheus Biosciences, Inc. (RXDX) Could Rally 26.51%: Here's is How to TradeJanuary 4, 2023 | msn.comHow Is The Market Feeling About Prometheus Biosciences?January 3, 2023 | finance.yahoo.comPrometheus Biosciences to Present at the 41st Annual J.P. Morgan Healthcare ConferenceDecember 23, 2022 | finance.yahoo.comWe're Hopeful That Prometheus Biosciences (NASDAQ:RXDX) Will Use Its Cash WiselyDecember 16, 2022 | benzinga.comLooking Into Prometheus Biosciences's Return On Capital EmployedFebruary 2, 2023 | Tradewins (Ad)Know Your Profit Potential BEFORE You Trade!I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! December 9, 2022 | msn.comWhy Prometheus Biosciences Stock Is FallingDecember 9, 2022 | finance.yahoo.comIs Prometheus Biosciences a Good Stock to Buy Right Now?December 8, 2022 | markets.businessinsider.comPrometheus Biosciences Prices Underwritten Offering Of About 4.55 Mln Shares At $110/shrDecember 8, 2022 | finance.yahoo.comPrometheus Biosciences, Inc. Announces Pricing of Public Upsized $500 Million Offering of Common StockDecember 8, 2022 | benzinga.comThinking about trading options or stock in Prometheus Biosciences, Apple, Chevron, DexCom, or Amazon?December 8, 2022 | marketwatch.comPrometheus Biosciences Shares Continue to Rally as Analysts Cheer >RXDXDecember 8, 2022 | finance.yahoo.comWhy Shares of Prometheus Biosciences Are Soaring This WeekDecember 7, 2022 | marketwatch.comPrometheus Biosciences Shares Soar Premarket After Positive PRA023 Studies >RXDXDecember 7, 2022 | marketwatch.comPrometheus Biosciences Shares Hit New High as Lead Candidate Advances >RXDXDecember 7, 2022 | finance.yahoo.comPrometheus shares rally 177% as it prepares to move drug into Phase 3 studiesDecember 7, 2022 | finance.yahoo.com2 Biotech Stocks Options Traders Love TodayDecember 7, 2022 | finance.yahoo.comPrometheus Biosciences, Inc. Announces Proposed Public Offering of Common StockDecember 7, 2022 | finance.yahoo.comPrometheus Bio 'Comfortably Overshoots' Drug's Expectations — And Shares Nearly TripleDecember 7, 2022 | investorplace.comWhy Is Prometheus Biosciences (RXDX) Stock Up 175% Today?December 7, 2022 | finance.yahoo.comPrometheus Biosciences Announces Positive Results for PRA023 in Both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a Studies Enabling Pathway to Both First-in-Class and Best-in-Class Anti-TL1A mAbNovember 12, 2022 | finance.yahoo.comPrometheus Biosciences Third Quarter 2022 Earnings: Beats ExpectationsNovember 9, 2022 | finance.yahoo.comPrometheus Biosciences, Inc. (RXDX) Reports Q3 Loss, Tops Revenue EstimatesNovember 9, 2022 | finance.yahoo.comPrometheus Biosciences Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate ProgressSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive RXDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Prometheus Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address RXDX Company Calendar Last Earnings11/09/2022Today2/02/2023Next Earnings (Estimated)3/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RXDX CUSIPN/A CIK1557421 Webignyta.com Phone858-422-4300FaxN/AEmployees72Year FoundedN/APrice Target and Rating Average Stock Price Forecast$117.10 High Stock Price Forecast$181.00 Low Stock Price Forecast$55.00 Forecasted Upside/Downside+6.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($3.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-90,190,000.00 Net Margins-1,847.71% Pretax Margin-1,847.71% Return on Equity-61.37% Return on Assets-50.27% Debt Debt-to-Equity Ratio0.11 Current Ratio11.19 Quick Ratio11.19 Sales & Book Value Annual Sales$3.13 million Price / Sales1,469.51 Cash FlowN/A Price / Cash FlowN/A Book Value$6.04 per share Price / Book18.16Miscellaneous Outstanding Shares41,940,000Free Float36,456,000Market Cap$4.60 billion OptionableNot Optionable Beta-0.52 Key ExecutivesMr. Mark C. McKenna (Age 42)Pres, CEO & Chairman Comp: $2.22MDr. Keith W. Marshall M.B.A. (Age 54)MBA, Ph.D., Chief Financial Officer Comp: $971.67kMr. Mark Stenhouse (Age 55)Chief Operating Officer Comp: $679.71kDr. Allison Luo M.D. (Age 49)Chief Medical Officer Comp: $827.97kDr. Olivier Laurent Ph.D. (Age 50)Chief Scientific Officer & Head of R&D Ms. Noel KurdiVP of Investor Relations & CommunicationsMr. Timothy K. Andrews Esq. (Age 43)Gen. Counsel & Sec. Ms. Nori Ebersole (Age 57)Chief People Officer Dr. Thierry Dervieux DABCC (Age 54)Ph.d., Pharm.d., Chief Devel. Officer of Diagnostics & Medical Laboratory Director Mr. Chris DoughtyChief Bus. OfficerMore ExecutivesKey CompetitorsIntra-Cellular TherapiesNASDAQ:ITCIAlkermesNASDAQ:ALKSMadrigal PharmaceuticalsNASDAQ:MDGLZai LabNASDAQ:ZLABPerrigoNYSE:PRGOView All CompetitorsInsiders & InstitutionsAR Asset Management Inc.Sold 233 shares on 2/1/2023Ownership: 0.121%Legato Capital Management LLCBought 9,631 shares on 2/1/2023Ownership: 0.023%Zurcher Kantonalbank Zurich Cantonalbank Sold 244 shares on 2/1/2023Ownership: 0.006%New York State Common Retirement FundSold 5,790 shares on 1/30/2023Ownership: 0.088%Bank of HawaiiBought 3,711 shares on 1/30/2023Ownership: 0.009%View All Insider TransactionsView All Institutional Transactions RXDX Stock - Frequently Asked Questions Should I buy or sell Prometheus Biosciences stock right now? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prometheus Biosciences in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RXDX shares. View RXDX analyst ratings or view top-rated stocks. What is Prometheus Biosciences' stock price forecast for 2023? 9 Wall Street analysts have issued 1 year price objectives for Prometheus Biosciences' shares. Their RXDX share price forecasts range from $55.00 to $181.00. On average, they predict the company's stock price to reach $117.10 in the next year. This suggests a possible upside of 6.8% from the stock's current price. View analysts price targets for RXDX or view top-rated stocks among Wall Street analysts. How have RXDX shares performed in 2023? Prometheus Biosciences' stock was trading at $110.00 at the start of the year. Since then, RXDX stock has decreased by 0.3% and is now trading at $109.67. View the best growth stocks for 2023 here. When is Prometheus Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 8th 2023. View our RXDX earnings forecast. How were Prometheus Biosciences' earnings last quarter? Prometheus Biosciences, Inc. (NASDAQ:RXDX) posted its earnings results on Wednesday, November, 9th. The biopharmaceutical company reported ($0.90) earnings per share for the quarter, missing analysts' consensus estimates of ($0.89) by $0.01. The biopharmaceutical company had revenue of $0.97 million for the quarter, compared to analyst estimates of $0.77 million. Prometheus Biosciences had a negative net margin of 1,847.71% and a negative trailing twelve-month return on equity of 61.37%. What other stocks do shareholders of Prometheus Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Prometheus Biosciences investors own include Cronos Group (CRON), Synergy Pharmaceuticals (SGYP), Immunomedics (IMMU), Freeport-McMoRan (FCX), (KITE) (KITE), La Jolla Pharmaceutical (LJPC), Sorrento Therapeutics (SRNE), TransEnterix (TRXC) and TherapeuticsMD (TXMD). When did Prometheus Biosciences IPO? (RXDX) raised $126 million in an initial public offering on Friday, March 12th 2021. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. SVB Leerink, Credit Suisse, Stifel and Guggenheim Securities served as the underwriters for the IPO. What is Prometheus Biosciences' stock symbol? Prometheus Biosciences trades on the NASDAQ under the ticker symbol "RXDX." Who are Prometheus Biosciences' major shareholders? Prometheus Biosciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Waypoint Capital Advisors LLC (0.41%), AR Asset Management Inc. (0.12%), New York State Common Retirement Fund (0.09%), Comerica Bank (0.08%), Moody Aldrich Partners LLC (0.03%) and Legato Capital Management LLC (0.02%). Insiders that own company stock include Joseph C Papa, Keith W Marshall, Mark C Mckenna, Mark Stenhouse and Perceptive Advisors Llc. View institutional ownership trends. How do I buy shares of Prometheus Biosciences? Shares of RXDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Prometheus Biosciences' stock price today? One share of RXDX stock can currently be purchased for approximately $109.67. How much money does Prometheus Biosciences make? Prometheus Biosciences (NASDAQ:RXDX) has a market capitalization of $4.60 billion and generates $3.13 million in revenue each year. The biopharmaceutical company earns $-90,190,000.00 in net income (profit) each year or ($3.35) on an earnings per share basis. How can I contact Prometheus Biosciences? Prometheus Biosciences' mailing address is 4545 Towne Centre Ct, SAN DIEGO, CA 92121-1900, United States. The official website for the company is ignyta.com. The biopharmaceutical company can be reached via phone at 858-422-4300 or via email at nkurdi@prometheusbiosciences.com. This page (NASDAQ:RXDX) was last updated on 2/2/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.